Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Observe Medical ASA is a Norway-based medtech company that develops, markets, and sells innovative medical technology products for global healthcare markets. Specializing in urine output measurement, anesthesiology, ICUs, and wound care, it offers key products like Sippi, a CE-marked digital and automated system for precise urine monitoring and biofilm control; Biim, a wireless pocketable ultrasound device for point-of-care imaging to guide needle and catheter insertions; and the Unometer portfolio, including Unometer Safeti Plus, Unometer 500, and AbdoPressure for manual urine drainage, collection, and intra-abdominal pressure measurement. Founded in 2009 and headquartered in Oslo with R&D in Gothenburg, Sweden, the company operates through subsidiaries and a global distributor network, serving patients, healthcare professionals, and hospitals primarily in Norway, Sweden, the US, and Europe. With a lean team of about five employees led by CEO Jorgen Mann, Observe Medical ASA focuses on improving patient outcomes, clinical data accuracy, and health economics through scalable product commercialization.
NOK 0.09
NOK 0.00 (-0.44%)
EOD Jul 1, 2026
The business is unprofitable at the operating level (-198.50% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 9.2%, steady but not accelerating.
Negative free cash flow of -NOK 26M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 19M
▲ +9.2% YoY
Net Income (TTM)
-NOK 49M
▲ +17.2% YoY
Op. Margin
-198.50%
▲ +59.2pp YoY
ROIC
-35.72%
▼ -0.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 26M
▲ +11.3% YoY
Op. Cash Flow (TTM)
-NOK 25M
▲ +12.0% YoY
Net Debt
NOK 19M
Cash & Equiv.
NOK 12M
3Y CAGR: -1.2%
Continue Research
Observe Medical ASA (OBSRV.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Observe Medical ASA scores 15/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Observe Medical ASA scores 15 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -198.5% operating margin and a -35.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh OBSRV.XOSL's valuation and scores 15/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.